Understand Medication and Prescriptions

Similar documents
Principles of Healthy Eating and Nutritional Needs of Individuals

SAMPLE. Certificate in Understanding Autism. Workbook 1 DIAGNOSIS PERSON-CENTRED. NCFE Level 2 ASPERGER S SYNDROME SOCIAL INTERACTION UNDERSTANDING

SAMPLE. Certificate in the Principles of End of Life Care PALLIATIVE CARE. Workbook 1. NCFE Level 2 ADVANCE CARE PLANNING COMMUNICATION SKILLS

SAMPLE. Certificate in Understanding Autism. Workbook 1 DIAGNOSIS PERSON-CENTRED. CACHE Level 2 ASPERGER SYNDROME SOCIAL INTERACTION UNDERSTANDING

Certificate in the Principles of Dementia Care

Certificate in the Principles of the Prevention and Control of Infection in Health Care Settings

SAMPLE. Certificate in Understanding Nutrition and Health. Workbook 1 HEALTHY DIET NUTRIENTS. CACHE Level 2 EATING DISORDERS ENERGY PHYSICAL ACTIVITY

Certificate in the Principles of End of Life Care

SAMPLE. Certificate in Understanding Behaviour that Challenges. Workbook 1 CONFLICT. CACHE Level 2 SUPPORT SYSTEMS POSITIVE REINFORCEMENT

PATIENT INFORMATION LEAFLET

PACKAGE LEAFLET: INFORMATION FOR THE USER Pulmicort Turbohaler budesonide. 1. What Pulmicort Turbohaler is and what it is used for

Lidocaine adult mouthwash 2mg in 1ml. Information for patients Pharmacy

PIL. ParaCet Flu 500 mg+250 mg/sachet Powder for oral solution paracetamol + ascorbic acid

PACKAGE LEAFLET: INFORMATION FOR THE USER. EASOFEN MAX STRENGTH 400mg FILM-COATED TABLETS. Ibuprofen

Quality, Safety and Sourcing in Unlicensed Medicines

Bonefos 400 mg capsules sodium clodronate

PACKAGE LEAFLET: INFORMATION FOR THE USER Paracodin 0.20% w/w Syrup (dihydrocodeine hydrogen tartrate)

Package Leaflet: INFORMATION FOR THE USER. PARACODIN 10 mg/g oral drops, solution (dihydrocodeine hydrorhodanide)

Patient leaflet: Information for the user. Paracetamol Galpharm 500mg tablets paracetamol

Patient Information Leaflet

Pain relief after birth and while breastfeeding. Information for mothers

Ventolin Accuhaler 200 micrograms salbutamol sulfate

Certificate in Understanding Common Childhood Illnesses

PACKAGE LEAFLET: INFORMATION FOR THE USER

All Saints First School Administering of Medicines Policy

PHOLCODINE. Please follow the instructions on the packaging of the medicine you purchased and in this leaflet before you start using pholcodine.

Drug Information Sheet("Kusuri-no-Shiori")

Lidocaine Hydrochloride BP 2% w/v in Lutrol F127 24% w/v Sterile Gel. Information for patients Pharmacy

Ca-C 1000 Calvive 1000 mg mg mg effervescent tablets

Testing Railway Safety Critical Workers for Drugs and Alcohol

Package leaflet: Information for the user. Bricanyl Turbohaler 0.5 mg/dose terbutaline sulfate

PATIENT GROUP DIRECTION (PGD) FOR THE SUPPLY OF DOXYCYCLINE 100MG TABLETS FOR THE FIRST-LINE TREATMENT OF CHLAMYDIA TRACHOMATIS INFECTION

TRIPROLIDINE. Please read this leaflet and the packaging of the medicine you purchased, carefully before you start using triprolidine.

PACKAGE LEAFLET: INFORMATION FOR THE USER

Package leaflet: Information for the user. Colecalciferol 3000 IU/ml Oral Solution (colecalciferol)

PACKAGE LEAFLET: INFORMATION FOR THE USER. XIFAXANTA 200 mg film-coated tablets Rifaximin

Package leaflet: Information for the user. Fluenz Tetra nasal spray suspension Influenza vaccine (live attenuated, nasal)

POISONS SCHEDULING. Monique Reyes Senior Pharmaceutical Officer Pharmaceutical Regulatory Unit NSW Ministry of Health

PACKAGE LEAFLET: INFORMATION FOR THE USER. DF118 Tablets 30mg (Dihydrocodeine Hydrogen Tartrate)

ICD-10 Readiness (*9/14/15) By PracticeHwy.com, Inc.

IBS Relief 135 mg Tablets Mebeverine Hydrochloride

Package leaflet: Information for the user Phosex 1000 mg Tablets Calcium acetate

Package leaflet: Information for the user. Bricanyl Respules 2.5 mg/ml Nebuliser Solution terbutaline sulfate

This leaflet answers some common questions about Momex SR Tablets.

Artemether 20mg/lumefantrine 120mg WHOPAR part 5 12/2011 Dispersible tablets (Novartis Pharma AG), MA069 LABELLING. Page 1 of 6

Guidance on Bulk Prescribing for Care Home Residents

RANIBOS 150mg Film-coated tablets; 300mg Film-coated tablets

Ventolin Injection 500 micrograms/ml salbutamol sulfate

Unit 204 Assist with the assembly of prescribed items

Review of Medicines Act 1968: informal consultation on issues relating to the PLR regime and homeopathy

This leaflet answers some common questions about TIBERAL tablets.

Epilepsy is a condition where you have repeated seizures (fits). There are many different types of seizures, ranging from mild to severe.

247 CMR BOARD OF REGISTRATION IN PHARMACY

MATERIAL SAFETY DATA SHEET WILKINSONS GROUT CLEANER

Prescription only medicines (POMs)

Nova Scotia Drug Information System

Food Fortification Regulations, 2016 (Gazetted on 24 October, 2016) ARRANGEMENT OF SECTIONS PART I PRELIMINARY

Ketorolac injection. Supportive care

PACKAGE LEAFLET: INFORMATION FOR THE USER. BritLofex Tablets 0.2mg LOFEXIDINE HYDROCHLORIDE

What is in this leaflet

Package leaflet: Information for the patient. NEGABAN 1g, powder for solution for injection or infusion Temocillin

HAVRIX 1440 and HAVRIX Junior

XYZAL 5 MG FILM-COATED TABLET

PREREQUISITES: VETA 1104, VETA 1201 and MATH This class must be taken before or in conjunction with VETT 2100.

PATIENT INFORMATION LEAFLET DYNAFIL RANGE

Thailand s experience in developing the Reclassification guideline

Package leaflet: Information for the user. Co-Codamol 30mg/500mg Capsules (Codeine Phosphate Hemihydrate and Paracetamol)

Guideline for the Rational Use of Controlled Drugs

LGP CLASSIC Oil Products

Guide to using your Medicine Safely

PATIENT INFORMATION LEAFLET. Nu-Seals 75 aspirin (acetylsalicylic acid)

PART 1.B SPC, LABELLING AND PACKAGE LEAFLET

PACKAGE LEAFLET: INFORMATION FOR THE USER. Bricanyl Turbohaler 0.5 mg/dose terbutaline sulphate

Package leaflet: Information for the user

AUDIT TOOL FOR SELF INSPECTION OF COMPLIANCE WITH QUALITY MANAGEMENT SYSTEM FOR PATIENT GROUP DIRECTIONS

Patient Group Directions (PGDs)

Consumer Medicine Information

PACKAGE LEAFLET: INFORMATION FOR THE USER

Package leaflet: Information for the user. SenEase 7.5 mg tablets. Sennosides

Getting the best from the medicines you buy

PACKAGE LEAFLET: INFORMATION FOR THE USER Histabentine 8 mg/16 mg tablets. Betahistine dihydrochloride

Pain relief after day surgery

THIS PATIENT GROUP DIRECTION HAS BEEN AGREED BY THE FOLLOWING ORGANISATIONS:

for adults engaged with the Family Wellbeing Service Isle of Wight In Community Pharmacy for Isle of Wight Public Health Commissioned Services

Some general information on hepatitis A infection is given at the end of this leaflet.

Package leaflet: Information for the patient. ROBAXIN mg Film-coated tablets for oral use Methocarbamol. 100 Tablets

Lesson 8 Using Medicines in Safe Ways

PACKAGE LEAFLET: INFORMATION FOR THE PATIENT. Estracyt Capsules Estramustine phosphate 140mg (as estramustine sodium phosphate)

Latex allergy. Occupational aspects of management

PATIENT INFORMATION LEAFLET TEXAMER

Package leaflet: Information for the user. Famvir 125, 250 and 500 mg film-coated tablets famciclovir

Package leaflet: Information for the user. HEPATECT CP 50 IU/ml solution for infusion. Human hepatitis B immunoglobulin for intravenous administration

MODULE 1: BASIC DRUG KNOWLEDGE

Jylamvo 2 mg/ml oral solution (Methotrexate) Guide for Healthcare Professionals. Information to minimise the risk of medication error

PACKAGE LEAFLET: INFORMATION FOR THE USER. Meptid 100 mg/ml Solution for Injection. Meptazinol

URSOSAN 250mg capsule, hard

GLUCOPHAGE 500 mg Merck Serono

PATIENT INFORMATION LEAFLET FOR TEXA 10 mg TABLETS AND TEXA SYRUP PROPRIETARY NAME, STRENGTH AND PHARMACEUTICAL FORM:

DRYDEN AQUA LTD Safety Data Sheet 18

Transcription:

Workbook 1 Understand Medication and Prescriptions Accountability Storage Administration Prescription Supply Legislation Level 2 Certificate in Understanding the Safe Handling of Medicines 1 L4W 2013

Information that should be supplied with medication Please read the following as it will help you to answer question 14. Patient Information Leaflet (PIL) The information supplied with medication is very important. It is a requirement of the MHRA that all medicine is supplied with a PIL. This applies to all medicines, including those bought over-the-counter or from a pharmacist, and those supplied on prescription. PILs should even be supplied when medicines are provided in a Monitored Dosage System. This information should always be readily available to your service users. By law, the information which must be supplied with all medication includes: Ingredients this includes the active ingredients of the medicine, as well as the ingredients used to make the tablet/capsule coating or the flavour/colour of the liquid. Dosage and administration this describes the strength of the medicine and how frequently it should be taken. Indications (uses) this should identify what the drug can be used for (e.g. to manage asthma or to treat certain types of infection). Contra-indications these are situations when the medicine should not be taken, or things that should not be done when taking the medication, e.g. not drinking alcohol during the course of the medication (it may alter its effectiveness); not suitable for certain age groups (e.g. children under 12); or if the person has another condition (e.g. is pregnant or has diabetes). Special precautions any special precautions that should be taken in order that the medicine is effective (e.g. take with food, or take on an empty stomach) or for certain groups of people (e.g. regular monitoring needed in individuals with renal/ kidney failure). Side effects any undesirable effects that the medicine may produce in some people (e.g. a rash or drowsiness). Interactions any interactions (reactions between two products) that the medicine may have with other drugs, which could be dangerous or make the treatment less effective. What to do if too much of the medication is taken. 42 L4W 2013

PIL should be written in clear and understandable terms, that both you and your service users can easily read. It should also contain the manufacturer and Product Licence Holder s names and addresses. Electronic copies of some PILs are available at www.emc.medicines.org.uk Data sheets and Summaries of Product Characteristics (SPCs) In addition to the PIL aimed at service users, companies are also required to produce a Data Sheet and SPC for each medicine. These are much more detailed information sheets for use by health professionals. Copies of data sheets and SPCs are available from the Manufacturer and are also available electronically at www.emc.medicines.org.uk Medicine instructions The pharmacist has overall responsibility for checking the prescription and ensuring that it is written correctly. When the pharmacist dispenses medication against a valid authorised prescription, the container in which the medication is supplied must be clearly labelled. By law, the label of any prescribed medicines dispensed by a pharmacist must include ALL of the following information: the service user s full name the name of the medication the dosage and frequency of the medication (for example how much and how often it should be taken) the date of supply the route to be taken/administered any special instructions for administration (for example take with food ) any warnings or cautions (for example avoid alcohol ) directions for use expiry date name and address of supplier/pharmacy the wording keep out of reach of children 43

Why is it important to seek information from the individual about their medication and condition? Please read the following as it will help you to answer question 15. Service users can be very useful sources of information. They often know a lot about their own condition and the medicines they are taking. They may be able to give you valuable information relating to: their medical condition and whether it is getting better or worse medicines which have not worked in the past and any side effects they have experienced with particular medicines any allergic reactions they have experienced with particular medicines how they prefer to take their medicine Person-centred care is an important aspect of supporting service users with their medication, and ongoing assessment of the individual s needs is essential to ensure that the person is fully supported. Giving someone the opportunity to discuss their requirements and any concerns they have can go a long way in increasing service user participation. If service users are consulted about their concerns and preferences, they are more likely to comply with their medication regime. In addition, all care staff have a responsibility to monitor the effectiveness of medication and to report any undesired effects. A person s condition can change from day to day or even hour to hour. It is important to establish whether the individual is experiencing any changes in condition, as this may be further affected by the medication the individual is taking. If service users are not given the opportunity to discuss their medication requirements and condition, they could be taking medication unnecessarily. 44 L4W 2013

Knowledge Activity 11: What sources of information are available to you within your workplace? Well done! You have now completed Workbook 1 and should attempt the assessments. If you require any help or guidance please contact your Assessor/Tutor. Workbook 1 45

Classification Monitoring Disclaimer Every effort has been made to ensure that the information contained within this learning material is accurate and reflects current best practice. All information provided should be used as guidance only, and adapted to reflect local practices and individual working environment protocols. All legislation is correct at the time of printing, but is liable to change (please ensure when referencing legislation that you are working from the most recent edition/amendment). Neither Learning for Work (L4W); nor their authors, publishers or distributors accept any responsibility for any loss, damage or injury (whether direct, indirect, incidental or consequential) howsoever arising in connection with the use of the information in this learning material. Copyright 2013 All rights reserved. All material contained within this manual, including (without limitation): text; logos; icons; and all other artwork is copyright material of Learning for Work (L4W), unless otherwise stated. No part of this publication may be reproduced, stored in a retrieval system, or transmitted in any form or by any means (electronic, mechanical, photocopying, recording or otherwise), without the prior permission of the copyright owners. If you have any queries, feedback or need further information please contact: Learning for Work (a trading arm of Learning at Work Ltd). Pure Offices, 1 Broad Gate, The Headrow, Leeds LS1 8EQ info@learning-work.co.uk www.learning-work.co.uk L4W-SHMv5 January 2013